MicrosoftTeams-image (5).png
Invea Therapeutics Research to be Showcased at the Prestigious 2023 DDW Meeting
26 avr. 2023 08h10 HE | Invea Therapeutics
GUILFORD, Conn., April 26, 2023 (GLOBE NEWSWIRE) -- Invea Therapeutics (Invea), a biotechnology company developing an artificial intelligence (AI) and machine learning (ML) powered pipeline of...
Invea Logo.jpg
Invea Therapeutics Appoints Mr. Jason Fenton to Its Board of Directors
06 déc. 2022 08h10 HE | Invea Therapeutics
- Mr. Fenton augments board expertise as the Company readies for Phase 1b/2 execution of lead program targeting mast cell biology - Company also primed to advance additional programs, including a...
AB Science annonce l
AB Science annonce la publication de l’étude clinique pivot de Phase 3 du masitinib dans les formes progressives de la sclérose en plaques dans la revue Neurology® Neuroimmunology & Neuroinflammation
22 févr. 2022 12h08 HE | AB Science
COMMUNIQUE DE PRESSE    PUBLICATION DE L’ETUDE CLINIQUE PIVOT DE PHASE 3 DU MASITINIB DANS LES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES DANS LA REVUE NEUROLOGY®: NEUROIMMUNOLOGY &...
AB Science announces
AB Science announces the publication of the masitinib positive pivotal Phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & Neuroinflammation
22 févr. 2022 12h08 HE | AB Science
PRESS RELEASE    PUBLICATION OF THE MASITINIB PIVOTAL PHASE 3 CLINICAL TRIAL IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS IN THE JOURNAL NEUROLOGY®: NEUROIMMUNOLOGY & NEUROINFLAMMATION Paris, 22...